Definium Therapeutics develops psychedelic-based therapeutics for psychiatric and neurological disorders. Backed by North Carolina Biotechnology Center.
About the role
The starting base pay range for this position is $180,000-$235,000, with compensation determined based on several factors including skill set, years of experience, and geographic location. Employees in this role may be entitled to additional compensation, including bonus and equity. Benefits information is listed on our Jobs Page. The Company provides competitive benefits to employees including:
What they're looking for
- Develop and execute patient support strategies to support the successful launch and commercialization of DT120
- Support development and implementation of potential REMS For DT120 via partnership with Compliance and other internal and external partners
- Design, continuously refine, and operationalize the end-to-end patient/ care partner journeys—from referral through long-term follow-up—ensuring a seamless and compliant treatment experience
- Translate patient support strategy into operational workflows, business requirements, CRM functionality, reporting needs, and digital capabilities to enable scalable execution
- Identify opportunities to leverage AI-enabled capabilities, automation, and digital engagement to enhance patient experience, operational efficiency, and proactive patient support
- Create external materials driving positive engagement with DT120 and Definium team members
More about this role
Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.
Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.
Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq...
Browse similar: Startup jobs · Remote jobs